PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-37.55%
Both yoy net incomes decline, with RVPH at -88.46%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
14.84%
D&A growth of 14.84% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
0.81%
Less SBC growth vs. RVPH's 4986.30%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
106.29%
Less working capital growth vs. RVPH's 391.43%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.80%
Lower 'other working capital' growth vs. RVPH's 545.90%. David Dodd would see fewer unexpected short-term demands on cash.
No Data
No Data available this quarter, please select a different quarter.
9.51%
Operating cash flow growth below 50% of RVPH's 33.13%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
38.16%
CapEx growth of 38.16% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.16%
We expand invests by 38.16% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
1171.17%
Issuance growth of 1171.17% while RVPH is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.